Workflow
Precigen: August Is Pivotal For This Biotech Innovator

Every once in a while, I get things right. On January 31, 2023 , I rated Precigen (NASDAQ: PGEN ) a HOLD at 1.62.Now,revisitingthecompanywithanewreport17monthslater,onJuly3,2025,thestockstillstandsat,yes,exactly1.62. Now, revisiting the company with a new report 17 months later, on July 3, 2025, the stock still stands at, yes, exactly 1.62.Sean Daly writes on ETFs, biotech and FINTECH solutions in the banking space. He teaches international finance and financial risk management at Pace University and was a visiting lecturer at Princeton University from 2005 to 2009. He was educated at Columbia University. ...